George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- April15 2003
- Volume 10
- Issue 7
WHERE THE MONEY WENT
Author(s)Michael Sheehan
Advertisement
Answer:
A feeble stock market has contributedto sustained outflows ofmoney from stock mutual funds.According to Lipper Inc, investorspulled $5 billion from their stockfunds in December 2002, leading toan overall net outflow of more than$10 billion for the year. Stock fundshad net withdrawals in 6 of the past 7months of the year. Money marketfunds, with their puny returns, hadalmost $50 billion in net outflows forthe year. Where did that money go? to bond funds, which posteda record $130 billion in new moneyin 2002, beating the previous high of$120 million in 1986.
Articles in this issue
about 18 years ago
Secure Tomorrow, Don't Lose Todayabout 18 years ago
Avoid the Turmoil of Insurance Mistakesabout 18 years ago
Bulletproof Your Car from the IRS' Aimabout 18 years ago
The PMD Answerman Q & Aabout 18 years ago
Impart Financial Values to Your Childrenabout 18 years ago
Watch Your Nest Egg's Financial Healthabout 18 years ago
Invest Some Land in Your 401(k) Accountabout 18 years ago
Plan According to Social Security Rulesabout 18 years ago
Discover Another Defined-Benefit Avenueabout 18 years ago
Know All Your Estate Planning BenefitsAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5